Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could taking epilepsy meds three times a day stop more seizures?

NCT ID NCT07490769

Disease control Sponsor: Waad Alkathiri Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether taking levetiracetam three times daily (instead of the usual twice daily) leads to more seizure-free days in adults with uncontrolled epilepsy. 120 participants will take the drug three times a day for 12 months and compare their results to their own past seizure records. The study also tracks side effects like dizziness and mood changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Levetiracetam (an anti-seizure medication)
What this could lead to
If successful, this could show that taking levetiracetam three times a day controls seizures better than the standard twice-daily schedule.
What could go wrong
This is a small, early-phase trial with only 120 participants, and it uses a self-controlled design rather than a placebo group. Side effects like dizziness or mood changes may also limit tolerability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older. * diagnosed with uncontrolled Epilepsy of any type (defined as one or more unprovoked seizures in the last 6 months) * On Levetiracetam monotherapy * Participants must have a documented history of Levetiracetam use for at least 12 months prior to enrollment. * on Levetiracetam high dose (1.5 - 3 g daily) Exclusion Criteria: * Younger than Aged 18 years * Received Levetiracetam intravenous within the last 24hr. * Co-administered with other antiepileptic drugs * Received other antiepileptic drugs in the last two weeks. * Pregnant women. * Renal impairment (Crcl \< 30) or Acute kidney injury

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • King Saud University

    RECRUITING

    Riyadh, Riyadh Region, 13321, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.